Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at blood sample analysis in predicting overall survival in patients with recurrent or metastatic head and neck cancer.
|Head and Neck Cancer||Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry|
|Study Design:||Observational Model: Other
Time Perspective: Retrospective
|Official Title:||Prediction of Overall Survival Using Mass Spectrometry Profiling in Head and Neck Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitors|
- Overall survival measured in weeks [ Time Frame: 1 month ]
|Actual Study Start Date:||July 8, 2008|
|Study Completion Date:||April 8, 2012|
|Primary Completion Date:||April 8, 2012 (Final data collection date for primary outcome measure)|
- To validate the mass spectrometry profile that is predictive of survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with EGFR inhibitors.
OUTLINE: Plasma and serum samples are analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and classified according to prognosis ("good" vs "poor") using a previously developed predictive algorithm.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898911
|Study Chair:||Christine Chung, MD||Vanderbilt-Ingram Cancer Center|